Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions

Thrombosis Research

Volumn 133, Issue 1, 2014, Pages 66-72

  Hosokawa, Kazuya ^a,b   Ohnishi, Tomoko ^a   Miura, Naoki ^c   Sameshima, Hisayo ^a   Koide, Takehiko ^b   Tanaka, Kenichi A ^d   Maruyama, Ikuro ^b  

^a Fujimori Kogyo CO   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Flow chamber; Platelet; Protease activated receptor; Thrombin; Thrombus formation

Indexed keywords

1 AMINO 3 CYCLOPROPYLAMINO 7 (4 ISOPROPYLBENZYL) 7H PYRROLO[3,2 F]QUINAZOLINE; 4 (1 BENZYL 1H INDAZOL 3 YL)BENZOIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; AR C 66096; COLLAGEN; FIBRIN; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 4 ANTAGONIST; THROMBIN RECEPTOR ANTAGONIST; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTERY; ARTICLE; BLOOD CLOTTING; CAPILLARY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE; THROMBOCYTE RICH PLASMA; VEIN;

ACS; ACTIVATING PEPTIDE; ACUTE CORONARY SYNDROME; ADENOSINE 5'-DIPHOSPHATE; ADP; AGGREGATION UNITS; AP; AREA UNDER THE AGGREGATION CURVE; ASP; ASPIRIN; AU; AUC; CFT; CLOT FORMATION TIME; CLOTTING TIME; CORN TRYPSIN INHIBITOR; CT; CTI; ENDOGENOUS THROMBIN GENERATION POTENTIAL; ETP; FLOW CHAMBER; GLYCOPROTEIN; GP; LAG TIME; LT; MAXIMUM CLOT FIRMNESS; MCF; OCCLUSION TIME; OT; PAR; PEAK HEIGHT; PH; PLATELET; PLATELET-POOR PLASMA; PLATELET-RICH PLASMA; PPP; PROTEASE-ACTIVATED RECEPTOR; PRP; R-TF; RECOMBINANT TISSUE FACTOR; T-TAS; TF; TG; THROMBIN; THROMBIN GENERATION; THROMBOXANE A(2); THROMBUS FORMATION; TIME TO PEAK; TISSUE FACTOR; TOTAL THROMBUS-FORMATION ANALYSIS SYSTEM; TTP; TXA(2);

FIBRINOLYTIC AGENTS; HUMANS; MICROSCOPY, CONFOCAL; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTOR, PAR-1; RECEPTORS, THROMBIN;

EID: 84890517579     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.10.037     Document Type: Article

References (50)

1. M.L. Kahn, Y.W. Zheng, W. Huang, V. Bigornia, D. Zeng, and S. Moff A dual thrombin receptor system for platelet activation Nature 394 1998 690 694
2. M.L. Kahn, M. Nakanishi-Matsui, M.J. Shapiro, H. Ishihara, and S.R. Coughlin Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin J Clin Invest 103 1999 879 887
3. D.J. Angiolillo, D. Capodanno, and S. Goto Platelet thrombin receptor antagonism and atherothrombosis Eur Heart J 31 2010 17 28
4. S. Leonardi, P. Tricoci, and R.C. Becker Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555 Drugs 70 2010 1771 1783
5. S. Leonardi, P. Tricoci, and K.W. Mahaffey Promises of PAR-1 inhibition in acute coronary syndrome Curr Cardiol Rep 14 2012 32 39
6. L. Martorell, J. Martinez-Gonzalez, C. Rodriguez, M. Gentile, O. Calvayrac, and L. Badimon Thrombin and protease-activated receptors (PARs) in atherothrombosis Thromb Haemost 99 2008 305 315
7. S.D. Tomasello, D.J. Angiolillo, and S. Goto Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events Expert Opin Investig Drugs 19 2010 1557 1567
8. L. Covic, M. Misra, J. Badar, C. Singh, and A. Kuliopulos Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation Nat Med 8 2002 1161 1165
9. M. Chintala, J. Strony, B. Yang, S. Kurowski, and Q. Li SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys Arterioscler Thromb Vasc Biol 30 2010 2143 2149
10. M. Dumas, F. Nadal-Wollbold, P. Gaussem, M. Perez, T. Mirault, and R. Letienne Antiplatelet and antithrombotic effect of F 16618, a new thrombin protease-activated receptor (PAR1) antagonist Br J Pharmacol 165 2012 1827 1835
11. R. Letienne, A. Leparq-Panissie, Y. Calmettes, F. Nadal-Wollbold, M. Perez, and B. Le Grand Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat Biochem Pharmacol 79 2010 1616 1621
12. P. Zhang, A. Gruber, S. Kasuda, C. Kimmelstiel, K. O'Callaghan, and D.H. Cox Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin Circulation 126 2012 83 91
13. R.C. Becker, D.J. Moliterno, L.K. Jennings, K.S. Pieper, J. Pei, and A. Niederman Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 2009 919 928
14. S. Goto, T. Yamaguchi, Y. Ikeda, K. Kato, H. Yamaguchi, and P. Jensen Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome J Atheroscler Thromb 17 2010 156 164
15. P. Tricoci, Z. Huang, C. Held, D.J. Moliterno, P.W. Armstrong, and F. Van de Werf Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33
16. W.S. Nesbitt, E. Westein, F.J. Tovar-Lopez, E. Tolouei, A. Mitchell, and J. Fu A shear gradient-dependent platelet aggregation mechanism drives thrombus formation Nat Med 15 2009 665 673
17. Z.M. Ruggeri Platelets in atherothrombosis Nat Med 8 2002 1227 1234
18. G.R. Sambrano, E.J. Weiss, Y.W. Zheng, W. Huang, and S.R. Coughlin Role of thrombin signalling in platelets in haemostasis and thrombosis Nature 413 2001 74 78
19. K. Hosokawa, T. Ohnishi, T. Kondo, M. Fukasawa, T. Koide, and I. Maruyama A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions J Thromb Haemost 9 2011 2029 2037
20. H.S. Ahn, C. Foster, G. Boykow, A. Stamford, M. Manna, and M. Graziano Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1- methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist Biochem Pharmacol 60 2000 1425 1434
21. R.G. Humphries, W. Tomlinson, A.H. Ingall, P.A. Cage, and P. Leff FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors Br J Pharmacol 113 1994 1057 1063
22. C.C. Wu, S.W. Huang, T.L. Hwang, S.C. Kuo, F.Y. Lee, and C.M. Teng YD-3, a novel inhibitor of protease-induced platelet activation Br J Pharmacol 130 2000 1289 1296
23. M.J. Swartz, H.L. Mitchell, D.J. Cox, and G.R. Reeck Isolation and characterization of trypsin inhibitor from opaque-2 corn seeds J Biol Chem 252 1977 8105 8107
24. S.R. Hanson, and K.S. Sakariassen Blood flow and antithrombotic drug effects Am Heart J 135 1998 S132 S145
25. A. Mailhac, J.J. Badimon, J.T. Fallon, A. Fernandez-Ortiz, B. Meyer, and J.H. Chesebro Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets Circulation 90 1994 988 996
26. M. Dumas, F. Nadal-Wollbold, P. Gaussem, M. Perez, T. Mirault, and R. Letienne Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist Br J Pharmacol 165 2012 1827 1835
27. S. Nylander, C. Mattsson, S. Ramstrom, and T.L. Lindahl Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation Br J Pharmacol 142 2004 1325 1331
28. H. Shankar, A. Garcia, J. Prabhakar, S. Kim, and S.P. Kunapuli P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation J Thromb Haemost 4 2006 638 647
29. C. Trumel, B. Payrastre, M. Plantavid, B. Hechler, C. Viala, and P. Presek A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase Blood 94 1999 4156 4165
30. K. Hosokawa, T. Ohnishi, M. Fukasawa, T. Kondo, H. Sameshima, and T. Koide A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process Microvasc Res 83 2012 154 161
31. K. Hosokawa, T. Ohnishi, H. Sameshima, N. Miura, T. Ito, and T. Koide Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions Thromb Haemost 109 2013 102 111
32. S. Leonardi, and R.C. Becker PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis Handb Exp Pharmacol 210 2012 239 260
33. H. Lee, S.A. Sturgeon, S.P. Jackson, and J.R. Hamilton The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions Thromb Haemost 107 2012 328 337
34. K.P. Rentrop Thrombi in acute coronary syndromes: revisited and revised Circulation 101 2000 1619 1626
35. V. Toschi, R. Gallo, M. Lettino, J.T. Fallon, S.D. Gertz, and A. Fernandez-Ortiz Tissue factor modulates the thrombogenicity of human atherosclerotic plaques Circulation 95 1997 594 599
36. D. Ardissino, P.A. Merlini, K.A. Bauer, E. Bramucci, M. Ferrario, and R. Coppola Thrombogenic potential of human coronary atherosclerotic plaques Blood 98 2001 2726 2729
37. A. Yamashita, E. Furukoji, K. Marutsuka, K. Hatakeyama, H. Yamamoto, and S. Tamura Increased vascular wall thrombogenicity combined with reduced blood flow promotes occlusive thrombus formation in rabbit femoral artery Arterioscler Thromb Vasc Biol 24 2004 2420 2424
38. D. Capodanno, D.L. Bhatt, S. Goto, M.L. O'Donoghue, D.J. Moliterno, and C. Tamburino Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials J Thromb Haemost 10 2012 2006 2015
39. A.J. Leger, L. Covic, and A. Kuliopulos Protease-activated receptors in cardiovascular diseases Circulation 114 2006 1070 1077
40. R. Shah Protease-activated receptors in cardiovascular health and diseases Am Heart J 157 2009 253 262
41. H. Lee, S.A. Sturgeon, J.K. Mountford, S.P. Jackson, and J.R. Hamilton Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice Br J Pharmacol 166 2012 2188 2197
42. M. Holinstat, B. Voss, M.L. Bilodeau, J.N. McLaughlin, J. Cleator, and H.E. Hamm PAR4, but not PAR1, signals human platelet aggregation via Ca2 + mobilization and synergistic P2Y12 receptor activation J Biol Chem 281 2006 26665 26674
43. B. Voss, J.N. McLaughlin, M. Holinstat, R. Zent, and H.E. Hamm PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis Mol Pharmacol 71 2007 1399 1406
44. A.D. Michelson Methods for the measurement of platelet function Am J Cardiol 103 2009 20A 26A
45. D.J. Angiolillo The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day Drugs 72 2012 2087 2116
46. K.A. Bauer Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa J Thromb Haemost 9 2011 12 19
47. R.D. Lopes Antiplatelet agents in cardiovascular disease J Thromb Thrombolysis 31 2011 306 309
48. C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, and J.P. Collet Antiplatelet agents for the treatment and prevention of atherothrombosis Eur Heart J 32 2011 2922 2932
49. W.C. Aird Spatial and temporal dynamics of the endothelium J Thromb Haemost 3 2005 1392 1406
50. H. Lee, and J.R. Hamilton Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease Pharmacol Ther 134 2012 246 259